Status
Conditions
Treatments
About
The main research question of this patient survey is to assess AF patients' preferences associated with different attributes which describe the different available anticoagulation treatment options (VKA or NOACs and, in case of NOACs, Apixaban, Dabigatran or Rivaroxaban).
VKA (Waran®) will be compared to Rivaroxaban.
Full description
The objective of this study is to investigate the following research questions in a cross-sectional survey of Swedish AF patients being treated either with a VKA or with a NOAC:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Inclusion criteria for AF patients in both the NOAC and the VKA groups:
Additional inclusion criterion for Group 1 (NOAC):
Additional inclusion criterion for Group 2 (VKA):
Exclusion criteria
Exclusion criteria for both groups:
382 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal